Loading…
Kwality Pharmaceuticals (KPL)₹3,856+4.62%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Kwality Pharmaceuticals reported sales of ₹162 Cr, up 46.0% from Jun 2025, and net profit of ₹25.93 Cr, up 116.4% year on year. For the year to Mar 2026, sales were ₹503 Cr and net profit ₹66.91 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.06 | 78.16 | 92.09 | 80.08 | 90.07 | 84.08 | 116 | 111 | 111 | 123 | 157 | 162 |
| Expenses | 54.02 | 60.99 | 70.94 | 62.94 | 69.96 | 66.93 | 90.04 | 86.99 | 86.01 | 93.03 | 118 | 121 |
| Operating Profit | 14.96 | 16.95 | 20.95 | 16.96 | 19.93 | 17.94 | 25.91 | 23.94 | 24.93 | 29.91 | 38.87 | 40.90 |
| OPM % | 22.0% | 21.0% | 22.0% | 22.0% | 22.0% | 21.0% | 22.0% | 21.9% | 23.0% | 24.0% | 25.0% | 24.9% |
| Other Income | 0.00 | 0.99 | −6.99 | 0.00 | 0.00 | 0.99 | 0.99 | 0.00 | 0.99 | 0.00 | 0.99 | 0.99 |
| Interest | 1.99 | 2.99 | 2.99 | 2.01 | 2.99 | 1.99 | 2.01 | 2.99 | 2.99 | 1.99 | 2.99 | 2.99 |
| Depreciation | 5.01 | 5.01 | 5.01 | 4.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 |
| Profit before tax | 7.99 | 9.99 | 5.99 | 10.99 | 12.98 | 10.99 | 18.99 | 17.01 | 17.99 | 21.99 | 31.99 | 33.97 |
| Tax % | 23.9% | 20.9% | 29.0% | 24.9% | 32.9% | 24.9% | 23.9% | 29.9% | 23.0% | 27.9% | 20.0% | 24.9% |
| Exceptional items | 0.00 | 0.00 | −4.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −0.99 | 0.00 | 0.00 |
| Net Profit | 5.98 | 7.98 | 3.99 | 7.99 | 7.98 | 8.98 | 13.97 | 11.98 | 13.98 | 15.96 | 24.97 | 25.93 |
| EPS (Rs) | 6.02 | 7.42 | 4.21 | 8.07 | 8.17 | 8.23 | 13.97 | 11.51 | 13.62 | 15.44 | 24.39 | 24.70 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74.06 | 98.20 | 137 | 166 | 139 | 262 | 457 | 251 | 307 | 371 | 503 | 554 |
| Expenses | 68.98 | 88.96 | 126 | 150 | 125 | 233 | 285 | 190 | 241 | 290 | 385 | 418 |
| Operating Profit | 4.99 | 8.98 | 11.96 | 15.96 | 13.95 | 28.93 | 171 | 60.86 | 65.83 | 79.71 | 118 | 135 |
| OPM % | 7.0% | 9.0% | 8.0% | 8.9% | 10.0% | 11.0% | 38.0% | 23.9% | 22.0% | 22.0% | 24.0% | 24.3% |
| Other Income | 0.00 | 0.99 | 0.99 | 0.99 | 3.99 | 1.99 | 3.99 | −13.99 | −4.99 | 1.99 | 1.99 | 2.97 |
| Interest | 0.99 | 2.01 | 1.99 | 2.01 | 2.99 | 3.01 | 2.99 | 6.99 | 9.99 | 10.01 | 10.99 | 10.96 |
| Depreciation | 2.01 | 3.01 | 3.01 | 3.01 | 4.01 | 6.01 | 11.01 | 15.02 | 20.05 | 18.04 | 20.02 | 20.04 |
| Profit before tax | 1.99 | 5.99 | 6.99 | 10.99 | 10.99 | 20.98 | 162 | 25.98 | 30.99 | 53.96 | 88.99 | 106 |
| Tax % | 47.9% | 41.9% | 39.0% | 31.0% | 24.9% | 30.0% | 25.9% | 25.0% | 24.0% | 25.9% | 25.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −11.99 | −4.99 | 0.00 | −0.99 | −0.99 |
| Net Profit | 0.99 | 2.99 | 3.99 | 7.99 | 7.98 | 14.97 | 120 | 18.96 | 23.95 | 39.91 | 66.91 | 80.84 |
| EPS (Rs) | 1.56 | 3.24 | 4.40 | 7.29 | 8.03 | 14.62 | 115.79 | 18.68 | 22.96 | 38.42 | 64.93 | 78.15 |
| Dividend payout % | 0.0% | 9.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.98 | 4.98 | 4.98 | 9.97 | 9.96 | 9.96 | 9.96 | 9.96 | 9.97 | 9.97 | 9.96 | 9.97 |
| Reserves | 15.03 | 17.04 | 20.03 | 19.03 | 27.03 | 36.04 | 51.10 | 171 | 190 | 214 | 255 | 322 |
| Borrowings | 7.99 | 12.99 | 18.97 | 25.97 | 28.98 | 34.95 | 40.94 | 53.93 | 89.90 | 97.85 | 112 | 130 |
| Other Liabilities | 9.99 | 16.99 | 26.02 | 40.01 | 39.01 | 52.10 | 63.99 | 105 | 70.03 | 71.80 | 71.03 | 130 |
| Total Liabilities | 36.99 | 51.00 | 71.00 | 95.98 | 105 | 133 | 166 | 341 | 361 | 394 | 447 | 592 |
| Fixed Assets | 13.03 | 13.03 | 17.05 | 20.06 | 29.08 | 43.11 | 57.11 | 92.17 | 120 | 139 | 146 | 156 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.01 | 12.03 | 14.04 | 0.00 | 0.00 | 17.04 |
| Investments | 0.99 | 1.99 | 3.99 | 4.98 | 4.98 | 3.99 | 4.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 23.97 | 36.98 | 49.96 | 69.94 | 70.92 | 85.95 | 102 | 237 | 226 | 255 | 302 | 420 |
| Inventories | 5.99 | 9.98 | 13.96 | 14.96 | 10.98 | 21.95 | 16.95 | 52.86 | 92.80 | 77.82 | 82.84 | 77.87 |
| Trade receivables | 9.03 | 18.06 | 23.08 | 37.11 | 38.15 | 30.08 | 36.12 | 69.22 | 72.23 | 114 | 154 | 281 |
| Cash & equivalents | 1.01 | 1.01 | 3.01 | 2.01 | 1.01 | 2.01 | 6.02 | 13.04 | 7.01 | 6.02 | 15.05 | 4.01 |
| Total Assets | 36.99 | 51.00 | 71.00 | 95.98 | 105 | 133 | 166 | 341 | 361 | 394 | 447 | 592 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.99 | −2.99 | 3.99 | −0.99 | 13.98 | 5.99 | 26.98 | 60.99 | 40.99 | 42.94 | 52.96 | 16.99 |
| Cash from investing activity | −1.01 | −2.01 | −7.02 | −6.02 | −12.03 | −18.04 | −23.05 | −63.11 | −48.08 | −26.06 | −29.08 | −35.07 |
| Cash from financing activity | 1.01 | 6.02 | 5.02 | 5.01 | −2.01 | 12.04 | 1.01 | 6.01 | 1.01 | −17.05 | −14.05 | 7.03 |
| Net cash flow | 0.99 | 0.00 | 1.99 | −0.99 | 0.00 | 0.00 | 3.99 | 2.99 | −5.98 | −0.99 | 9.98 | −10.98 |
| Capex | 1.43 | 2.58 | 6.78 | 6.34 | 11.81 | 20.77 | 23.37 | 55.13 | 47.59 | 29.81 | 24.99 | 48.86 |
| Free cash flow | 0.00 | −4.99 | −1.99 | −6.99 | 1.99 | −11.99 | 2.99 | 4.99 | −3.99 | 16.97 | 27.97 | −28.97 |
| CFO / OP % | 51.0% | −30.0% | 76.0% | 21.0% | 107.9% | 61.9% | 115.0% | 59.0% | 78.0% | 67.0% | 85.0% | 32.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 62 | 88 | 83 | 97 | 83 | 78 | 49 | 54 | 103 | 135 | 151 | 202 |
| Inventory days | 60 | 66 | 70 | 53 | 33 | 93 | 37 | 96 | 309 | 186 | 166 | 110 |
| Days payable | 39 | 62 | 64 | 79 | 51 | 95 | 57 | 62 | 116 | 105 | 111 | 143 |
| Cash conversion cycle | 85 | 93 | 90 | 73 | 67 | 77 | 30 | 90 | 297 | 217 | 208 | 170 |
| Working capital days | 34 | 40 | 19 | 17 | 19 | 42 | 23 | 59 | 117 | 100 | 97 | 127 |
| ROCE % | 9.0% | 13.1% | 19.1% | 19.0% | 22.1% | 18.0% | 26.0% | 98.1% | 19.1% | 16.1% | 18.1% | 24.0% |
For the Jun 2026 quarter, Kwality Pharmaceuticals reported sales of ₹162 Cr, up 46.0% year on year and net profit of ₹25.93 Cr, up 116.4% year on year. The operating margin was 24.9%.
Kwality Pharmaceuticals' sales for the year to Mar 2026 were ₹503 Cr; over the last twelve months they were ₹554 Cr.
Net profit for the year to Mar 2026 was ₹66.91 Cr, and ₹80.84 Cr over the last twelve months. Earnings per share over the same trailing period were ₹78.15.
Kwality Pharmaceuticals reported borrowings of ₹130 Cr at Mar 2026, against cash and equivalents of ₹4.01 Cr.
Cash from operations was ₹16.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹28.97 Cr.